# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* CHANEY PAUL G				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ DirectorOfficer (give title below)Other (specify below)						
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 05/01/2015												
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution E any (Month/Day	ate, if	(Ins		ction	(A) or	Disposed 3, 4 and 5  (A) or ant (D)	of (D)	Beneficia Reported	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  Continuous of the following of the fo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock 05/01		05/01/2015			,	A		15,32 (1)	26 A	\$ 0	23,659		D			
Reminder:	Report on a s	separate line fo		Derivative So	ecurit	ies Ac	equire	Pers cont the f	ons wi ained i orm di	ho respo in this fo splays a of, or Ber	rm are curre reficial	e not requ ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)
Security	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da any	4. Transaction Code (Instr. 8)		5. 6. I Number and		6. Da	ns, convertible securi Date Exercisable Id Expiration Date Month/Day/Year)		7. T Am Und Sec	ount of erlying arities tr. 3 and Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form o Derivat Securit Direct ( or India	Beneficia Ownersh (Instr. 4)	
				Code	V	(A)	(D)	Date Exer	cisable	Expiratio Date	n Title	Amount or Number of Shares				

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
CHANEY PAUL G C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X					

## **Signatures**

/s/ Authorized Signatory*	05/05/2015
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person received Restricted Shares from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan, which are subject to vesting and certain other conditions. 13% of the Restricted Shares are fully vested as of the Transaction Date, and 29% vest on each of June 30, 2015, September 31, 2015, and December 31, 2015.

#### Remarks:

\*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.